Foghorn Therapeutics Inc.
NASDAQ:FHTX
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Price:
4.78
USD
8.14%
Market Closed
Market Cap:
$280m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Foghorn Therapeutics Inc.
NASDAQ:FHTX
|
US |
|
B
|
Brazil Potash Corp
AMEX:GRO
|
CA |
|
P
|
Petrovietnam Power Corp
VN:POW
|
VN |
|
Norske Skog ASA
OSE:NSKOG
|
NO |
|
FreakOut Holdings Inc
TSE:6094
|
JP |
|
I
|
Invicta Holdings Ltd
JSE:IVT
|
ZA |
|
W
|
Winpak Ltd
TSX:WPK
|
CA |
|
SAGE Therapeutics Inc
NASDAQ:SAGE
|
US |
|
R
|
Refinverse Group Inc
TSE:7375
|
JP |
|
N
|
New Era Helium Inc
NASDAQ:NEHC
|
US |
|
Yakutskaya Toplivno-Energeticheskaya Kompaniya PAO
MOEX:YAKG
|
RU |
|
L
|
Linedata Services SA
SWB:LN4
|
FR |
|
Shriram Asset Management Co Ltd
BSE:531359
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
FHTX
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 4.78 USD,
Foghorn Therapeutics Inc.
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FHTX Multiples-Based Value
LOCKED
Multiples Across Competitors
FHTX Competitors Multiples
Foghorn Therapeutics Inc. Competitors
Foghorn Therapeutics Inc. Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Foghorn Therapeutics Inc.
NASDAQ:FHTX
|
270.8m USD | 8.8 | -3.6 | -1.4 | -1.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD | 6.3 | 91.9 | 15.2 | 21.1 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
361.6B USD | 111.3 | -1 738.3 | 16 147.7 | -1 823.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD | 5.2 | 24.6 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD | 5.9 | 20.3 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD | 9.5 | 28.7 | 21.6 | 22.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.1 | 34.7 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
